Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form

Summary

The first step of coagulation factor XIII (FXIII) activation involves cleavage of the FXIII activation peptide (FXIII-AP) by thrombin. However, it is not known whether the FXIII-AP is released into plasma upon cleavage or remains attached to activated FXIII. The aim of the present work was to study the structure of free FXIII-AP, develop an assay for FXIII-AP determination in human plasma, and to answer the question whether FXIII-AP is released into plasma. We used ab-initio modeling and molecular dynamics simulations to study the structure of free FXIII-AP. We raised monoclonal and polyclonal antibodies against FXIII-AP and developed a highly sensitive and specific ELISA method for direct detection of FXIII-AP in human plasma. Structural analysis showed a putative different conformation of the free FXIII-AP compared to FXIII-AP bound to the FXIII protein. We concluded that it might be feasible to develop specific antibodies against the free FXIII-AP. Using our new FXIII-AP ELISA, we found high levels of FXIII-AP in in-vitro activated plasma samples and serum. We showed for the first time that FXIIIAP is detached from activated FXIII and is released into plasma, where it can be directly measured. Our findings may be of major clinical interest in regard to a possible new marker in thrombotic disease.

Keywords

factor XIII - activation peptide - activation marker - molecular dynamics simulations

• References

• 1 Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIIIdeficient plasma with the purified zymogen. J Clin Invest 1983; 71: 1336-1341.
• 2 Sakata Y, Aoki N. Significance of cross-linking of α 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-542.
• 3 Kohler HP, Stickland MH, Ossei-Gerning N. et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
• 4 Kohler HP, Mansfield MW, Clark PS. et al. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. Thromb Haemost 1999; 82: 1202-1203.
• 5 Kohler HP, Ariens RA, Mansfield MW. et al. Factor XIII activity and antigen levels in patients with coronary artery disease. Thromb Haemost 2001; 85: 569-570.
• 6 Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thromb Haemost 2003; 90: 434-438.
• 7 Lorand L. Factor XIII: Structure, activation, and interactions with fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 291-311.
• 8 Schwartz ML, Pizzo SV, Hill RL. et al. The subunit structures of human plasma and platelet factor XIII (fibrin- stabilizing factor). J Biol Chem 1971; 246: 5851-5854.
• 9 Yee VC, Pedersen LC, Le Trong I. et al. Three-dimensional structure of a transglutaminase: Human blood coagulation factor XIII. Proc Natl Acad Sci USA 1994; 91: 7296-7300.
• 10 Yee VC, Pedersen LC, Bishop PD. et al. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res 1995; 78: 389-397.
• 11 Janus TJ, Lewis SD, Lorand L. et al. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry 1983; 22: 6269-6272.
• 12 Ariëns RAS, Philippou H, Chandrasekaran N. et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects crosslinked fibrin structure. Blood 2000; 96: 988-995.
• 13 Tammen H, Möhring T, Kellmann M. et al. Mass spectrometric phenotyping of Val34Leu polymorphism of blood coagulation factor XIII by differential peptide display. Clin Chem 2004; 50: 545-551.
• 14 Weiss MS, Metzner HJ, Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett 1998; 423: 291-296.
• 15 Brooks BR, Bruccoleri RE, Olafson BD. et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983; 4: 187-217.
• 16 Lazaridis T, Karplus M. Effective energy function for proteins in solution. Proteins 1999; 35: 133-152.
• 17 Frishman D, Argos P. Knowledge-based protein secondary structure assignment. Proteins 1995; 23: 566-579.
• 18 DeLano WL. The PyMOL Molecular Graphics System 2002; Available at http://www.pymol.org
• 19 Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14: 33-38.
• 20 Ariëns RAS, Kohler HP, Mansfield MW. et al. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2012-2016.
• 21 Ferrara P, Caflisch A. Folding simulations of a three-stranded antiparallel beta-sheet peptide. Proc Natl Acad Sci USA 2000; 97: 10780-10785.
• 22 Ferrara P, Apostolakis J, Caflisch A. Thermodynamics and kinetics of folding of two model peptides investigated by molecular dynamics simulations. J Phys Chem B 2000; 104: 5000-5010.
• 23 Hiltpold A, Ferrara P, Gsponer J. et al. Free energy surface of the helical peptide Y(MEARA)6. J Phys Chem B 2000; 104: 10080-10086.
• 24 Ichinose A. The physiology and biochemistry of factor XIII. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. 3rd edn, Vol. 1. Edinburgh; Livingstone: 1994: 531-546.
• 25 Yorifuji H, Anderson K, Lynch GW. et al. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988; 72: 1645-1650.
• 26 Hornyak TJ, Bishop PD, Shafer JA. α -Thrombincatalyzed activation of human platelet factor XIII: relationship between proteolysis and factor XIIIa activity. Biochemistry 1989; 28: 7326-7332.